13 listed sites: United States (13) - 15 Nov `24TEV-53408 antibody treatment for nonsegmental vitiligo

TEV-53408 antibody treatment for nonsegmental vitiligo

Official title: A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo

Status: Closed to new participants

Description:

Teva Branded Pharmaceutical Products R&D LLC plans to enroll about 66 participants. The experimental antibody blocks IL-15, an immune signal that helps pigment-destroying T cells survive. Researchers hope it will reduce the immune attack on melanocytes and allow skin color to return. Possible risks include injection or infusion reactions, headache, and infections; longer-term risks are still being studied. People ages 18 to 75 may qualify. The study is underway but is no longer accepting new participants.

Start date: November 11, 2024

Completion date: January 31, 2029

Organizer: Teva Branded Pharmaceutical Products R&D LLC

Contact: Teva Medical Expert, MD

Link: https://clinicaltrials.gov/study/NCT06625177

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference TEV-53408 antibody treatment for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Белые пятна на теле? Витилиго?

    Гид по Витилиго — ваш компас в лабиринте загадочной болезни и непростых решений. Здесь всё по-честному, по делу и на понятном языке. Вы найдёте здесь: Объяснения, что происходи...

  • Which skin conditions can be mistaken for vitiligo?

    Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...

  • Is there a special diet for vitiligo?

    Recent research highlights the potential of diet and nutrition in managing vitiligo, offering an alternative where traditional therapies may be lacking. However, the relationshi...